Elicio Therapeutics Inc.

NASDAQ: ELTX · Real-Time Price · USD
11.80
1.96 (19.92%)
At close: Aug 18, 2025, 1:44 PM

Elicio Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.17M 1.17M 1.17M n/a n/a n/a n/a n/a n/a n/a 1.65M 27.59M 29.05M 29.59M 27.94M 2.46M 1.83M 2.02M
Cost of Revenue
1.43M 1.44M 1.46M 1.16M 869K 576K 334K 289K 579K 579K 759K 1.17M 1.1M 1.31M 1.08M 695K 967K 1.26M
Gross Profit
-266K -278K -290K -1.16M -869K -576K -334K -289K -579K -579K 889K 26.41M 27.95M 28.28M 26.86M 1.76M 859K 751K
Operating Income
-44.65M -45.48M -44.98M -40.9M -41.33M -38.18M -35.74M -32.31M -27.31M -25.77M -32.45M -11.85M -21.84M -33.85M -25.56M -54.04M -49.87M -48.9M
Interest Income
868K 837K 777K 547K 608K 510K 370K 349.83K 113.83K 74.83K 1.43M 2.25M 2.35M 2.47M 1.11M 235.8K 125.8K 1.8K
Pretax Income
-54.61M -51.28M -51.9M -46.84M -38.66M -38.99M -35.2M -32.9M -29.44M -29.18M -35.39M -13.85M -22.35M -32.13M -24.08M -67.84M -69.81M -73.08M
Net Income
-54.61M -51.28M -51.9M -46.84M -38.66M -38.99M -35.2M -32.9M -29.44M -29.18M -35.39M -13.85M -22.35M -32.13M -24.08M -67.84M -69.81M -73.08M
Selling & General & Admin
11.95M 11.61M 11.33M 11.8M 12.17M 12.26M 11.9M 10.33M 8M 6.36M 8.31M 10.65M 13.22M 16.18M 13.55M 12.52M 14.63M 15.78M
Research & Development
32.7M 33.88M 33.66M 29.1M 29.16M 25.92M 23.85M 21.98M 19.31M 19.41M 25.56M 27.91M 36.57M 45.95M 38.87M 43.29M 36.1M 33.86M
Other Expenses
-1.15M -1.17M -1.18M -1.16M -869K -576K -286K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
43.49M 44.31M 43.81M 39.74M 40.46M 37.6M 35.46M 32.31M 27.31M 25.77M 33.87M 38.56M 49.79M 62.13M 52.42M 55.81M 50.73M 49.65M
Interest Expense
741K 596K 456K 224K 88K 753K 1.06M 1.15M 2.22M 2.58M 2.24M 2.15M 1.07M n/a n/a 5.6M 8.18M 8.67M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 2.68M 5.6M 5.6M 5.6M 2.92M n/a n/a n/a
Cost & Expenses
44.65M 45.48M 44.98M 40.9M 41.33M 38.18M 35.74M 32.31M 27.31M 25.77M 34.1M 39.44M 50.89M 63.44M 53.5M 56.5M 51.7M 50.91M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a 463.52K 463.52K 463.52K 463.52K n/a n/a n/a 1.8K 1.8K 1.8K 1.8K
Shares Outstanding (Basic)
16.06M 12.95M 12.2M 13.58M 11.28M 10.27M 9.6M 4.08M 3.1M 3.2M 3.1M 3.18M 3.09M 3M 3M 2.98M 2.97M 13.31M
Shares Outstanding (Diluted)
16.06M 12.95M 12.2M 13.58M 11.28M 10.27M 9.6M 4.08M 3.1M 3.2M 3.1M 3.18M 3.09M 3M 3M 2.98M 2.97M 13.31M
EPS (Basic)
-4.07 -4.05 -4.33 -4.11 -5.33 -7.13 -8.49 -9.71 -9.37 -9.3 -11.54 -4.42 -7.41 -10.79 -6.51 -15.35 -12.46 -9.43
EPS (Diluted)
-4.07 -4.05 -4.33 -4.11 -5.33 -7.13 -8.49 -9.71 -9.37 -9.3 -11.54 -4.42 -7.41 -10.79 -6.51 -15.35 -12.46 -9.43
EBITDA
-52.72M -49.52M -50.26M -45.56M -37.54M -37.5M -33.69M -31.12M -26.4M -25.79M -32.11M -10.8M -20.67M -31.31M -23.43M -61.68M -61.08M -63.9M
EBIT
-53.87M -50.68M -51.44M -46.62M -38.58M -38.24M -34.14M -31.75M -27.21M -26.6M -33.15M -11.7M -21.29M -32.13M -24.08M -62.24M -61.63M -64.41M
Depreciation & Amortization
1.15M 1.17M 1.18M 1.16M 1.14M 1.35M 1.11M 1.06M 1.08M 684.21K 864.21K 846.21K 773.21K 874K 698.3K 621.3K 545.3K 509.3K